Proactive Investors - Run By Investors For Investors

Netscientific associate Vortex Biosciences makes first commercial sale

VTX-1 is a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs) for analysis
picture of blood
VTX-1 is a fully automated benchtop system for collecting Circulating Tumour Cells

Vortex BioSciences, a portfolio company of AIM-listed IP firm NetScientific PLC(LON:NSCI), has made the first direct commercial sale of its VTX-1 Liquid Biopsy System.

VTX-1 is a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs) for analysis.

READ: NetScientific’s Glycotest subsidiary allowed Chinese patent for liver cancer blood test

The process traps unlabelled CTCs in microscale vortices from whole blood, allowing researchers to better understand cancer progression.

Francois Martelet, Vortex BioSciences’s chairman and NetScientific’s chief executive, said it was an important step towards commercialising VTX.

The system combines industry-leading purity and high CTC capture rates of between 65%-75%, which we believe can give researchers the opportunity to open new windows into our understanding of cancer. 

READ: NetScientific investee company's technology showcased in prestigious academic journal

Gene Walther, Vortex’s chief executive, added: "The reaction to the VTX-1 throughout the marketplace has been unbelievably positive, confirming both the tremendous potential CTCs offer and the unique value of the VTX-1."

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
salmon
January 30 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use